Drug Discovery - SKIL Platform

SKIL® (Sareum Kinase Inhibitor Library) is based on an amido-oxazole chemical template which can be adapted to inhibit many kinase types. The template is amenable to parallel synthesis and structure based design. Physico-chemical properties (Molecular weight, CLogP, solubility) are generally excellent. SKIL compounds have demonstrated sub-nM potencies with good selectivity. Lead compounds have been develepoed that are suitable for administration via the i.v. or oral routes.

The intellectual property on the chemical template, specific examples and their use is embodied in a published patent (WO2008/139161), which has a favourable examiner's report.

The SKIL platform has generated lead compounds for Sareum's Aurora+FLT3, Aurora+ALK and VEGFR-3 kinase cancer programmes and its TYK2 and FLT3 auto-immune disease programmes.

We routinely cross-screen programme compounds against a panel of kinase enzymes to identify new programme opportunities. In principle, structure-based library design can be utilised to generate lead inhibitors against a specific kinase of interest. These leads have very low exposure to competitors' "submarine" patents (patents that have been filed but not yet published) as Sareum has a strong IP position on the chemical series.

SKIL is a registered trade mark of Sareum Ltd